98 results about "Phenylacetones" patented technology

The invention relates to an Escherichia coli engineering strain for producing 2, 3-pentanediol as well as a construction method and application of the Escherichia coli engineering strain, and the method comprises the following steps: constructing recombinant plasmids pACYC-IlvA *-ThrA * BC for expressing an IlvA * gene of threonine deaminase, a ThrA gene of asparaginic acid kinase I, a Thr B gene of homoserine kinase and a ThrC gene of threonine synthetase; the method comprises the following steps: constructing a recombinant plasmid pRSF-Ilv2C-Aro10 for expressing an Ilv2C gene of acetohydroxy acid synthetase and an Aro10 gene of propiophenone dehydrogenase; and chemically converting the recombinant plasmid pACYC-IlvA *-ThrA * BC and the recombinant plasmid pRSF-Ilv2C-Aro10, and transferring the recombinant plasmid pACYC-IlvA *-ThrA * BC and the recombinant plasmid pRSF-Ilv2C-Aro10 into escherichia coli so as to obtain the escherichia coli engineering strain for producing the 2, 3-pentanediol. According to the escherichia coli engineering strain, the biosynthesis of 1.61 g / L of 2, 3-pentanediol is realized by using L-threonine and 40 g / L of glucose.

The present invention provides an SLC6A19 inhibitor compound, a pharmaceutical composition, a preparation method, and a use. The compound has a good SLC6A19 inhibitory effect, and is used for the treatment of SLC6A19-mediated disorders and / or diseases, such as phenylketonuria, and the preparation of drugs for such disorders or diseases.

The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and / or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and / or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.

This invention discloses a method for preparing a biomimetic actuating material based on inkjet printing patterned construction of a reed inner membrane hydrogel composite. The method includes inkjet printing a reed inner membrane; adding N-isopropylacrylamide, N,N-methylenebisacrylamide, and 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone to an aqueous solution of nano-clay to obtain a hydrogel prepolymer; placing the inkjet-printed reed inner membrane on a glass slide, adding the hydrogel prepolymer, covering and sealing it, and then placing it in ice water for photopolymerization to obtain the reed inner membrane hydrogel composite biomimetic actuating material. This invention uses an inkjet printer to print pigment ink onto the surface of a natural reed inner membrane for patterning, and then rapidly forms a strong mechanical interlocking structure with poly(N-isopropylacrylamide) hydrogel, resulting in strong bonding. The method is simple, and the actuating material exhibits excellent photothermal conversion efficiency, mechanical properties, and patterning capabilities, thereby enabling rapid actuation, ultra-high power actuation, and various complex biomimetic actuator designs.

The invention discloses a recombinant microorganism for producing hydroxytyrosol as well as a construction method and application of the recombinant microorganism. According to the recombinant microorganism, 3-deoxy-D-arabinoheptulose-7-phosphate synthetase aroGfbr, chorismate mutase / pre-benzoic acid dehydrogenase tyrAfbr, 4-hydroxyphenylacetic acid 3-hydroxylase HpaBC, phenylpyruvate decarboxylase ARO10 and alcohol dehydrogenase ADH6 are subjected to overexpression, and the recombinant microorganism can be used for preparing the recombinant microorganism. The genome of the gene naturally comprises a citrate synthase coding gene gltA and a tyrosine aminotransferase coding gene tyrB; the original promoter of the gltA and / or the original promoter of the tyrB are / is replaced by a time sequence promoter PrrnC-37. When the recombinant microorganism is used for producing hydroxytyrosol, the production efficiency can be improved, and the production cost of hydroxytyrosol can be reduced.

Methods and devices are provided for capturing and using quantitative and qualitative results from point-of-collection devices for different diagnostic assays on a mobile device application. In one nonlimiting embodiment, these methods and devices are used in the diagnosis and / or monitoring of phenylketonuria (PKU).

The present disclosure relates to an optimized PAH gene and expression cassette and uses thereof, and discloses a polynucleotide molecule encoding a PAH protein. The polynucleotide molecule, expression cassette, expression vector, viral particle, and / or pharmaceutical composition disclosed herein can be used to effectively, sustainably, and stably express human PAH in the liver at a relatively low dose, thereby maintaining the phenylalanine concentration in a subject's blood at a low level for a long period of time and stably, and can be used to treat phenylketonuria.

The invention relates to an expiratory gas marker for evaluating a mental fatigue state, and a method and a device for identifying the mental fatigue state. The expired gas marker at least comprises an organic compound combination consisting of oxalic acid, 3-phenyllactic acid, benzene, acetone and 3-methylpentane; oxalic acid, 3-phenyllactic acid, benzene, acetone and 3-methylpentane in exhaled air are associated with mental fatigue, and a brand-new biomarker combination with higher specificity is provided. In addition, a new modal metabolic data is provided for mental fatigue discrimination, and a multi-modal mental fatigue diagnosis model based on VOCs-HRV-PVT is constructed.

Various methods and compositions of treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-related diseases or disorders are presented herein. Also presented herein are methods of increasing CoQ10 biosynthesis, and methods of determining whether a subject will benefit from a CoQ10 or CoQ10 alternative treatment. Also presented herein are pharmaceutical compositions and dosage forms comprising 4-hydroxymandelic acid (4-HMA), and / or its metabolites. Further presented herein are compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase-like (HPDL). Further presented herein are methods of identifying and / or assessing modulators of HPDL. Yet further presented herein are example methods and systems for isotopic labelling in cells by metabolizing cells in the presence of gaseous isotopic tracer.

The invention discloses application of phenylpyruvic acid in prevention and control of citrus canker, and belongs to the field of treatment of agricultural canker. The invention discloses a new application of phenylpyruvic acid in treating and / or preventing citrus canker, and the effective dosage of phenylpyruvic acid is 0.01-1.5 M. The phenylpyruvic acid is externally applied, so that the scab area of the citrus canker can be reduced to a great extent, and the attack degree of the canker is reduced. In addition, the content of phenylpyruvic acid in citrus can be increased through multiple technologies, and the phenylpyruvic acid can be used for canker-resistant molecular breeding.

Provided herein are phenylalanine-degrading enzyme variants for use in degrading phenylalanine and in treating phenylketonuria (PKU). More specifically, provided herein are phenylalanine-degrading enzyme variants that exhibit increased thermal stability and physicochemical resistance as measured by residual phenylalanine-degrading activity following challenge.

This invention discloses a load 32 The preparation method of the ultrathin sheet-like chitosan hydrogel applicator of P includes: (1) preparing a chitosan aqueous solution; (2) adding methacrylic anhydride to the chitosan aqueous solution to obtain methacrylated chitosan; (3) preparing a methacrylated chitosan aqueous solution; (4) adding 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylphenylacetone to the methacrylated chitosan aqueous solution to obtain a chitosan hydrogel precursor solution; (5) coating the inner wall of a polytetrafluoroethylene mold with a superhydrophilic coating; (6) adding Na2H 32 PO4 aqueous solution and chitosan hydrogel precursor solution are added to the mold, stirred and then cured by light; (7) the cured hydrogel is taken out and sealed between two layers of transparent tape. This application can prepare an ultra-thin hydrogel applicator, thereby reducing the obstruction of radiation by the hydrogel material itself and enhancing the therapeutic effect of the applicator.

Disclosed are naphthyl compounds comprising a ureido piperidine-1-carboxamide or ureido piperidine-1-formate moiety, compositions thereof, and methods of use thereof for treating or preventing diseases or conditions associated with abnormal levels of amino acids, such as phenylketonuria, hyperphenylalaninemia, diabetes, and chronic kidney disease, by modulating SLC6A19 transport.

The invention provides a phenylpyruvate decarboxylase mutant with multi-site mutation and application of the phenylpyruvate decarboxylase mutant in production of tyrosol, and belongs to the technical field of bioengineering. The problem of low yield of tyrosol is solved. The phenylpyruvate decarboxylase mutant comprises a phenylpyruvate decarboxylase mutant, and the phenylpyruvate decarboxylase mutant is obtained by mutating any two or three sites of the 93rd site, the 106th site, the 153rd site, the 220th site, the 242nd site, the 273rd site and the 285th site by taking amino acid as shown in SEQ ID NO.2 as a starting sequence. The method is mainly used for increasing the yield of tyrosol.

The application relates to the technical field of high polymer materials, and discloses a high-strength heat-resistant photovoltaic cutting pad and a preparation method thereof. The preparation method comprises the following steps: S1: silane-modified hydrotalcite, methylphenyl dimethoxysilane and dimethyl vinyl ethoxysilane are added into a mixed solvent of toluene and acetone, an aqueous KOH solution is added, reaction is carried out at 55-60 DEG C for 6-8 hours, low-boiling-point products are removed by increasing the temperature, and the silane-modified hydrotalcite is obtained by filtration, washing and drying; and S2: PP resin, the silane-modified hydrotalcite, a compatilizer, a heat-resistant modifier, an antioxidant and an initiator are mixed and granulated in a double-screw extruder, a blank plate is prepared by extrusion and calendering, and the photovoltaic cutting pad is obtained by milling and cutting. The photovoltaic cutting pad comprises the following raw materials in parts by mass: 60-70 parts of PP resin, 10-15 parts of the silane-modified hydrotalcite, 5-10 parts of the heat-resistant modifier and 0.1-0.2 parts of the initiator.

This invention discloses a method for preparing and applying o-pyrazolylphenylacetone olefin derivatives. The method involves dispersing o-pyrazolylphenylpropenol compounds, aryl aldehyde compounds, and a catalyst in an organic solvent to react and obtain o-pyrazolylphenylacetone derivatives. The method for synthesizing o-pyrazolylphenylacetone derivatives of this invention has advantages such as inexpensive raw materials, simplicity and efficiency, mild reaction conditions, high atom economy, easy product purification, and green economy. The obtained products can be directly applied as potential drugs in the pharmaceutical field, showing broad application prospects.

This utility model discloses a mother liquor recovery device for crude p-methylphenylacetone, comprising: a support plate and auxiliary components. The support plate has second mounting grooves on both its front and rear sides on its lower surface. A hydraulic pump is fixedly connected to the inner surface of the second mounting groove. A hydraulic rod is fixedly connected to the output end of the hydraulic pump. A lower pressure plate is fixedly connected to the lower surface of the hydraulic rod. An auxiliary rod is fixedly connected to the upper surface of the lower pressure plate. A limit plate is fixedly connected to the outer surface of the auxiliary rod, and a spring abuts against the upper surface of the limit plate. Through the sliding guide structure of the auxiliary rod and the fixed block, the horizontal offset of the lower pressure plate during lifting is controlled to a minimal range, ensuring the uniformity and accuracy of the mother liquor recovery pressure. The rigid support characteristics of the spring evenly distribute the pressure transmitted by the hydraulic rod to the support plate, reducing fatigue wear of key components and extending the service life of core components such as the hydraulic pump and hydraulic rod.

The invention discloses a covalent organic framework material for purifying aluminum ions in a propiophenone production process and a preparation method of the covalent organic framework material, the two-dimensional covalent organic framework material with carboxyl is prepared from 2, 4, 6-trihydroxybenzene-1, 3, 5-tricarboxaldehyde (THBT) and 4, 4, 6-trihydroxybenzene-1, 3, 5-tricarboxaldehyde (THBT), and the two-dimensional covalent organic framework material with carboxyl is a covalent organic framework material with carboxyl. A two-dimensional covalent organic framework with a terphenyl and hydroxyl structure is formed by condensation of a 4, 4 '-diamino-[1, 1': 4 ', 1'-triphenyl]-2 ', 5'-diol (DMTPD) building unit, and then the two-dimensional covalent organic framework is modified by ethylene diamine tetraacetic acid dianhydride (EDTAD) to obtain the high-molecular polymer. The covalent organic framework material is high in crystallinity, rich in carboxyl, capable of being combined with aluminum ions in the propiophenone synthesis process, beneficial to adsorption separation of the aluminum ions and good in application prospect in the field of adsorption separation.

The invention discloses a moisture-proof curing agent applied to a PCB (Printed Circuit Board) coating and a preparation process of the moisture-proof curing agent, and relates to the technical field of PCB protective materials. The invention discloses a moisture-proof curing agent applied to a PCB coating. The invention discloses a nano-silicon dioxide modified epoxy resin, which is prepared from the following raw materials in parts by weight: 30 to 50 parts of epoxy resin, 20 to 35 parts of polyurethane prepolymer, 10 to 15 parts of nano-silicon dioxide, 5 to 10 parts of methyltrimethoxysilane, 3 to 8 parts of gamma-aminopropyltriethoxysilane, 0.5 to 2 parts of dibutyltin dilaurate, 2 to 5 parts of 2-hydroxy-4 '-(2-hydroxyethoxy)-2-methyl propiophenone and 1 to 3 parts of antioxidant 1076. The self-repairing coating is prepared from, by weight, 20-30 parts of epoxy resin, 8-12 parts of tripropylene glycol diacrylate, 5-8 parts of polytetrafluoroethylene micro powder, 4-7 parts of self-repairing microcapsules and 20-30 parts of modified acrylic resin. The moisture-proof curing agent has the advantages of good moisture-proof performance, low water absorption, excellent mechanical properties such as hardness and adhesive force, good temperature resistance and impact resistance, self-repairing function, high repairing efficiency, strong weatherability, no obvious change after ultraviolet aging, and excellent performance in all aspects, and is suitable for PCB coating protection.

The application discloses a 4-hydroxyphenylpyruvate dioxygenase mutant for synthesizing beta-hydroxyisovaleric acid and an application thereof, and belongs to the technical field of bioengineering. The 4-hydroxyphenylpyruvate dioxygenase mutant is constructed, and the catalytic efficiency of the 4-hydroxyphenylpyruvate dioxygenase can be significantly improved. The 4-hydroxyphenylpyruvate dioxygenase and L-amino acid deaminase constructed are used together for catalyzing preparation of beta-hydroxyisovaleric acid, and the yield of HMB can reach 7 g / L, and the conversion rate is 77%. Compared with the 4-hydroxyphenylpyruvate dioxygenase capable of catalyzing L-leucine to generate HMB at present, the yield of HMB is higher. The HMB yield of BbHPPD A366P / M359V / N382S is 3.7 times that of the wild enzyme, and the industrialization process of enzyme conversion method for producing HMB is accelerated.

The application belongs to the technical field of biotechnology, and provides application of an engineered Enterococcus faecalis capable of expressing human phenylalanine hydroxylase in a medicine for treating phenylketonuria, a plasmid with a human-derived phenylalanine hydroxylase gene after codon optimization of the Enterococcus faecalis is introduced into the Enterococcus faecalis, so that the human phenylalanine hydroxylase is expressed in the intestinal tract. Experimental results show that the human phenylalanine hydroxylase is successfully expressed in the Enterococcus faecalis through genetic engineering technology; the engineered Enterococcus faecalis can significantly metabolize phenylalanine in an in-vitro culture medium system; meanwhile, the engineered Enterococcus faecalis can significantly treat phenylketonuria, and can reduce plasma phenylalanine of a phenylketonuria suckling mouse by 46.8% after 4 weeks of treatment. It is indicated that the engineered Enterococcus faecalis has an outstanding therapeutic effect in preventing and / or treating phenylketonuria.

The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein.These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

This invention discloses a recombinant *E. coli* strain for producing phenyllactic acid, a lactate dehydrogenase mutant, a whole-cell catalytic method for preparing phenyllactic acid, and the application of the aforementioned recombinant *E. coli* strain or lactate dehydrogenase mutant in the catalytic preparation of phenylpyruvic acid from phenyllactic acid. This invention significantly improves catalytic efficiency by modifying the 52nd amino acid of lactate dehydrogenase through site-directed mutagenesis. After mutating glutamine (Q) to valine (V) at position 52 of the *Lactobacillus mucosa* lactate dehydrogenase, the catalytic efficiency is significantly improved even at low cell density (OD). 600 =15) and substrate 15 g / L conditions, almost complete conversion was achieved; and combined with high-density catalysis and surface display optimization, the yield of phenyl lactic acid was increased while the downstream separation and purification costs were significantly reduced, greatly enhancing the potential for industrial production.

This disclosure provides compositions, systems, and methods for targeting, editing, modifying, or manipulating the genome of a host cell at one or more locations in a DNA sequence within a cell, tissue, or object. A genetically modified system for treating phenylketonuria (PKU) is described. In one embodiment, this disclosure relates to a pharmaceutical composition comprising the above system and a pharmaceutically acceptable excipient or carrier, wherein the pharmaceutically acceptable excipient or carrier is selected from the group consisting of plasmid vectors, viral vectors, vesicles, and lipid nanoparticles.

The application discloses a construction method of a recombinant strain of Zymomonas mobilis for producing melanin and application of the recombinant strain. The recombinant strain is transformed with an expression plasmid containing a p-hydroxyphenylpyruvate dioxygenase hppD gene and a phenylalanine-4-hydroxylase pah gene. The nucleotide sequence of the p-hydroxyphenylpyruvate dioxygenase hppD gene is shown as SEQ ID NO:1, and the nucleotide sequence of the phenylalanine-4-hydroxylase pah gene is shown as SEQ ID NO:2. The application successfully realizes the heterologous synthesis of melanin in the Zymomonas mobilis by introducing the HGA synthesis pathway based on the analysis of the melanin production pathway. The introduction of the key metabolic pathway endows the Zymomonas mobilis with a brand-new metabolic capacity, and greatly expands the application boundary of the Zymomonas mobilis in the field of biosynthesis.

This invention belongs to the field of pharmaceutical synthesis, specifically relating to a method for preparing etorizine hydrochloride and its intermediates. Specifically, it involves reacting propionyl chloride and ethylbenzene at -80 to -50°C to obtain p-ethylphenylacetone, which is then reacted with piperidine and paraformaldehyde to form a salt, yielding etorizine hydrochloride. The method for preparing p-ethylphenylacetone provided by this invention can obtain a product with a low content of compound II. Using this as a raw material to prepare etorizine hydrochloride simplifies post-processing, improves yield, and ensures that the content of compound III meets pharmacopoeia standards, making it suitable for industrial production.

In one aspect, the present disclosure provides a method for the synthesis of methylone HCl using 3,4-methylenedioxypropiophenone (MDP) as a starting material. In another aspect, the present disclosure provides stereoisomers of methylone. In another aspect, the present disclosure provides phenethylamines or cathinones covalently attached to a chemical moiety in a prodrug form. The prodrug forms described herein allow for the sustained / sustained / controlled delivery of the parent compound, phenethylamine or cathinone, to the blood system in a manner that extends the duration of therapeutic effect.

The invention provides a compound capable of stabilizing phenylalanine hydroxylase mutation, a pharmaceutical composition as well as a preparation method and application of the compound. The compound can effectively recover the activity of phenylalanine hydroxylase mutant protein, is used for treating diseases and / or diseases caused by phenylalanine hydroxylase mutation, such as phenylketonuria, and is used for preparing medicines for the diseases and / or diseases.